- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Waltham Today
By the People, for the People
OptimizeRx Reports Strong Fourth Quarter and Full Year 2025 Financial Results
Revenue reaches record $109.4 million, adjusted EBITDA hits $24.3 million for the full year
Published on Mar. 5, 2026
Got story updates? Submit your updates here. ›
OptimizeRx Corp. (Nasdaq: OPRX), a leading provider of healthcare technology solutions, announced strong financial results for the fourth quarter and full year 2025. Revenue reached a record $109.4 million for the full year, up 19% from 2024, while adjusted EBITDA totaled $24.3 million, reflecting a margin of more than 20%. The company also paid off $2 million in debt during Q4 and authorized a $10 million share repurchase program.
Why it matters
OptimizeRx's robust financial performance demonstrates the strength and durability of its healthcare technology platform, which helps life sciences companies reach and engage with healthcare providers and patients. The company's ability to achieve 'Rule of 40' status, a key industry benchmark, highlights its profitable growth model and positions it well for continued success in the evolving healthcare landscape.
The details
OptimizeRx reported Q4 revenue of $32.2 million and full year revenue of $109.4 million, a 19% increase from 2024. Gross profit increased 9% year-over-year in Q4 to $24.1 million, and full year gross profit was $73.6 million. The company achieved record Q4 net income of $5.0 million and adjusted EBITDA of $12.0 million, while full year adjusted EBITDA reached $24.3 million. OptimizeRx also paid off $2 million in debt during Q4 and ended the year with $23.4 million in cash and cash equivalents.
- OptimizeRx reported its Q4 and full year 2025 results on March 5, 2026.
- The company's board of directors authorized a $10 million share repurchase program effective March 12, 2026, expiring on the earlier of March 15, 2027 or when the full $10 million in shares have been repurchased.
The players
OptimizeRx Corp.
An American healthcare technology company that provides solutions to help life sciences companies reach and engage with healthcare providers and patients.
Stephen L. Silvestro
The CEO of OptimizeRx.
What they’re saying
“We delivered a strong fourth quarter, exceeding both consensus and internal expectations, with revenue of $32.2 million and adjusted EBITDA of $12.0 million. For the full year, revenue reached a record $109.4 million and adjusted EBITDA totaled $24.3 million, reflecting more than 20% margin and nearly $19 million in operating cash flow.”
— Stephen L. Silvestro, CEO, OptimizeRx (GlobeNewswire)
What’s next
The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.
The takeaway
OptimizeRx's strong financial performance in 2025, including record revenue and adjusted EBITDA, demonstrates the company's ability to execute on its profitable growth strategy and position itself as a leading healthcare technology provider. The authorization of a $10 million share repurchase program further underscores the company's commitment to driving shareholder value creation.
